NCT05203679 - Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

April 16, 2024

Study Completion Date

June 30, 2028

Conditions

Hemophilia B

Interventions

GENETIC

Single dose intravenous injection of BBM-H901

Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver.

Trial Locations (9)

100005

Peking Union Medical College Hospital, Beijing

230022

Anhui Provincial Hospital, Hefei

300020

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

450003

Henan Cancer Hospital, Zhengzhou

510515

Nanfang Hospital Southern Medical University, Guangzhou

518025

The Second People's Hospital of Shenzhen, Shenzhen

650032

The second Affiliated Hospital of Kunming Medical University, Kunming

063000

North China University of Science and Technology Affiliated Hospital, Tangshan

030001

The Second Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors

lead

Shanghai Xinzhi BioMed Co., Ltd.

INDUSTRY